Home » Tenders » Americas » USA » Total Rna Sequencing with Option to Increase Tender, USA - 100533073

Total Rna Sequencing with Option to Increase Tender, USA - 100533073

HEALTH AND HUMAN SERVICES, DEPARTMENT OF has floated a tender for Total Rna Sequencing with Option to Increase. The project location is USA and the tender is closing on 05 May 2024. The tender notice number is NOI-NIAID-24-2217118, while the TOT Ref Number is 100533073. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : USA

Summary : Total Rna Sequencing with Option to Increase

Deadline : 05 May 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 100533073

Document Ref. No. : NOI-NIAID-24-2217118

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Purchaser : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Contracting Office Address : Bethesda, MD 20892
Primary Point of Contact : Maliaka Pinkney
maliaka.pinkney@nih.gov
Phone Number 2406695308

Secondary Point of Contact : Jesse D Weidow
weidowjd@niaid.nih.gov
Phone Number 4063759783
USA
Email :maliaka.pinkney@nih.gov

Tender Details

Description

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Psomagen, Inc. for total RNA sequencing with an option to increase. Due to continuity protocols, and to avoid introducing variables in the testing results, we must use the same source throughout the life of the study.

The National Institute of Allergy and Infectious Diseases (NIAID), has a study to sequence RNA obtained from the PBMC-s of the same set of patients whose nasal epithelium was earlier sequenced. The purpose of this research is to understand transcriptomics signatures of asthma and asthma severity in the African Diaspora. The RNASeq generated from the PBMCs will be compared to RNASeq generated from nasal epithelium on the same study subjects to allow NIAID to identify common and unique signatures from two different target tissues relevant to this disease. Psomagen has sequenced the RNA samples that were obtained from the Nasal epithelium from the subjects in the CAAPA study. For the uniformity and comparability, NIAID request to use Psomagen to sequence the PBMC samples so as the expand on the pre-existing resources in CAAPA. Psomagen is ISO 9001 and ISO13485 certified to provide high quality data in our entire sample preparation and sequencing processes. Psomagen Clinical Laboratory in the US practices under CLIA certified and CAP accredited environment which assures higher standard of accuracy, reliability, and timeliness of test results.

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be consider...
Active Contract Opportunity Notice ID NOI-NIAID-24-2217118 Related Notice Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier NATIONAL INSTITUTES OF HEALTH
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Apr 26, 2024 04:04 pm EDT
Original Response Date: May 05, 2024 12:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: May 20, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
NAICS Code: 541380 - Testing Laboratories and Services

Place of Performance: Bethesda, MD 20892 USA